| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Retracted
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
2.75
|
|
2
|
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.
|
Cancer Prev Res (Phila)
|
2010
|
1.80
|
|
3
|
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.
|
Am J Pathol
|
2007
|
1.79
|
|
4
|
Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
|
Cancer Res
|
2009
|
1.65
|
|
5
|
Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features.
|
Cancer
|
2008
|
1.50
|
|
6
|
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
|
Drug Resist Updat
|
2010
|
1.46
|
|
7
|
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
|
Clin Cancer Res
|
2009
|
1.39
|
|
8
|
Regulation of SRC family kinases in human cancers.
|
J Signal Transduct
|
2011
|
1.32
|
|
9
|
Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer.
|
Clin Cancer Res
|
2009
|
1.32
|
|
10
|
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
|
Mol Cancer Ther
|
2007
|
1.29
|
|
11
|
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
|
Sci Transl Med
|
2012
|
1.27
|
|
12
|
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
|
Cancer
|
2010
|
1.15
|
|
13
|
EphA2 in the early pathogenesis and progression of non-small cell lung cancer.
|
Cancer Prev Res (Phila)
|
2009
|
1.11
|
|
14
|
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
|
J Clin Oncol
|
2008
|
1.06
|
|
15
|
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.
|
Mol Cancer Ther
|
2008
|
1.04
|
|
16
|
Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer.
|
Clin Cancer Res
|
2010
|
1.02
|
|
17
|
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
|
Mol Cancer Ther
|
2012
|
1.01
|
|
18
|
STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma.
|
Clin Cancer Res
|
2011
|
0.99
|
|
19
|
Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance.
|
Lung Cancer
|
2013
|
0.95
|
|
20
|
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
|
Radiother Oncol
|
2012
|
0.95
|
|
21
|
Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
|
J Natl Cancer Inst
|
2013
|
0.94
|
|
22
|
Spindle epithelial tumor with thymus-like differentiation: A case report and comprehensive review of the literature and treatment options.
|
Head Neck
|
2014
|
0.92
|
|
23
|
Src inhibitors in lung cancer: current status and future directions.
|
Clin Lung Cancer
|
2010
|
0.91
|
|
24
|
Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
|
Anticancer Drugs
|
2008
|
0.88
|
|
25
|
Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
|
J Transl Med
|
2013
|
0.86
|
|
26
|
Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC.
|
J Thorac Oncol
|
2013
|
0.77
|
|
27
|
Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival.
|
Head Neck
|
2012
|
0.77
|
|
28
|
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
|
Cancer
|
2010
|
0.75
|
|
29
|
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
|
Nat Rev Clin Oncol
|
2009
|
0.75
|
|
30
|
Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.
|
Anticancer Drugs
|
2015
|
0.75
|